Cargando…

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

BACKGROUND: A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic drugs (DMARDs). The objective of this study was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roodenrijs, Nadia M. T., de Hair, Maria J. H., Wheater, Gill, Elshahaly, Mohsen, Tekstra, Janneke, Teng, Y. K. Onno, Lafeber, Floris P. J. G., Hwang, Ching Chang, Liu, Xinyu, Sasso, Eric H., van Laar, Jacob M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245625/ https://www.ncbi.nlm.nih.gov/pubmed/30458871 http://dx.doi.org/10.1186/s13075-018-1750-5

Ejemplares similares

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study
por: Wheater, Gillian, et al.
Publicado: (2018)

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody (HORUS TRIAL)
por: Elshahaly, Mohsen, et al.
Publicado: (2013)

Bone marker reference range study: a comparison of the manufacturer’s reference range and laboratory healthy volunteer results to patients with rheumatoid arthritis
por: Wheater, Gillian, et al.
Publicado: (2013)

The clinical utility of bone marker measurements in osteoporosis
por: Wheater, Gillian, et al.
Publicado: (2013)

Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)

Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients
por: van der Leeuw, Matthijs S., et al.
Publicado: (2023)

Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study
por: Verhoeven, Maxime M A, et al.
Publicado: (2021)

Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials
por: Verhoeven, Maxime M. A., et al.
Publicado: (2022)

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
por: Messelink, Marianne A., et al.
Publicado: (2022)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
por: van der Leeuw, Matthijs S., et al.
Publicado: (2022)

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis
por: Cuppen, Bart V. J., et al.
Publicado: (2016)

Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis
por: Huo, Yinghe, et al.
Publicado: (2015)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity
por: Teng, YK Onno, et al.
Publicado: (2012)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review
por: Verhoeven, M. M. A., et al.
Publicado: (2019)

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
por: van der Leeuw, Matthijs S., et al.
Publicado: (2020)

The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial
por: Jurgens, M. S., et al.
Publicado: (2020)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate
por: Verhoeven, Maxime M A, et al.
Publicado: (2020)

Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio
por: Gosselt, Helen R., et al.
Publicado: (2020)

Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search
por: Roodenrijs, Nadia M T, et al.
Publicado: (2022)

Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013)

Gout: An old disease in new perspective – A review
por: Ragab, Gaafar, et al.
Publicado: (2017)

Rituximab and its potential for the treatment of rheumatoid arthritis
por: Bryant, Adam, et al.
Publicado: (2006)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Update on the use of rituximab for intractable rheumatoid arthritis
por: Looney, R John
Publicado: (2009)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment
por: Ghiti Moghadam, Marjan, et al.
Publicado: (2018)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
por: Kobak, Şenol, et al.
Publicado: (2013)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
por: Kilic, Levent, et al.
Publicado: (2018)

COVID-19 related thrombi in ascending and descending thoracic aorta with peripheral embolization: a case report
por: Buikema, Jan W, et al.
Publicado: (2021)

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
por: Williams, Jason H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t72rjcpit6qkj7mlsfqkv02orl